Rizonib 250 mg (Capsule)

Unit Price: ৳ 750.00 (3 x 10: ৳ 22,500.00)

Strip Price: ৳ 7,500.00

Medicine Details

Category	Details
Generic	Crizotinib
Company	Drug international ltd

First FDA-approved biomarker-driven therapy for both ALK-positive and ROS1-positive metastatic NSCLC. Only FDA-approved drug for ROS1-positive NSCLC.

Mode of Action:
- Inhibitor of receptor tyrosine kinases including ALK, c-Met, ROS1, and RON
Absorption: Median time to achieve peak concentration: 4 to 6 hours
Distribution: Extensive distribution into tissues from plasma
Metabolism: Predominantly metabolized by CYP3A4/5
Elimination: Mean apparent plasma terminal half-life: 42 hours

Recommended Dose: 250 mg orally, twice daily
Geriatric Use: No observed differences in safety or efficacy compared to younger patients
Pediatric Dose: Safety and effectiveness not established
Renal Impairment: 250 mg orally, once daily in severe renal impairment
Hepatic Impairment: Caution advised in patients with hepatic impairment

CYP3A Inhibitors: Concurrent use should be avoided with strong CYP3A inhibitors
CYP3A Inducers: Concurrent use should be avoided with strong CYP3A inducers
CYP3A Substrates: Concurrent use should be avoided with CYP3A substrates with narrow therapeutic indices

Pregnancy: Can cause fetal harm, effective contraception advised
Lactation: Patients should not breastfeed during treatment and for 45 days after the final dose

Hepatotoxicity monitoring
Discontinue in patients with ILD/Pneumonitis
Monitor for QT interval prolongation
Regular monitoring for bradycardia
Ophthalmological evaluation for severe visual loss
Females of reproductive potential should be advised about the potential risk to a fetus

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children